Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neuromuscular Immune-related Adverse Events of Checkpoint Inhibitors. A Case Series at a Third-level Hospital in Argentina
Autoimmune Neurology
P4 - Poster Session 4 (11:45 AM-12:45 PM)
14-005
Immune checkpoint inhibitors (ICI’s) are an effective cancer immunotherapy, especially in advanced oncologic disease. Among the numerous adverse events reported, those that affect the neuromuscular system (PNS-irAEs), such as Myasthenia gravis (MG), Inflammatory Myopathies (IM), and neuropathies, are highly related to morbidity and mortality rates.
To Describe a case series of neuromuscular adverse events in oncology patients on immune checkpoint inhibitor treatment.
Patients receiving ICI’s treatment who presented with neuromuscular syndromes were included from December 2017 to August 2023.

Nine patients were identified, 8 were males. The median age was 76 years (62-79). Among the oncologic diseases, metastatic melanoma was the most frequent (33%). The ICI’s received included pembrolizumab (n=6, 66%), nivolumab (n=2, 22%), and durvalumab (n=1, 12%). The PNS-irAEs included the debut of MG associated with MI (n=6, 66%), MG (n=1, 12%), and necrotizing myositis (n=2, 22%). Six of these patients also had myocarditis (3 cases of MG, MI, and Myocarditis overlap syndrome).

The median number of ICI’s cycles received was 1.7 (range 1-2). The median number of days after the first dose until PNS-irAEs was 28 (16-60). All patients discontinued the ICI’s. Treatment included corticosteroids (n=9), intravenous immunoglobulin (n=8), plasma exchange (n=1), and Rituximab (n=1). 8 patients required an intensive care unit stay, with a median stay of 20 days. 5 patients showed positive response to treatment, while the remaining patients did not survive.


In this series, the most common PNS-irAEs were MG and MI, although rare, these events can be potentially fatal. Due to the widespread use of ICI’s, physicians should remain aware to enable prompt recognition and management of PNS-irAEs to improve the prognosis.
Authors/Disclosures
Rodrigo J. Sanjinez, Sr., MD (Hospital Italiano de Buenos Aires)
PRESENTER
Dr. Sanjinez has nothing to disclose.
Rocio V. Marquez, MD (Hospital Italiano de Buenos Aires) Dr. Marquez has nothing to disclose.
No disclosure on file
No disclosure on file
Mariela Bettini, MD (Hospital Italiano DE. BS. AS.) Dr. Bettini has nothing to disclose.
No disclosure on file
No disclosure on file
Carolina L. Azcona, MD (Hospital Italiano de Buenos Aires) Dr. Azcona has nothing to disclose.
Marcelo Rugiero Rodriguez Marcelo Rugiero Rodriguez has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi.